Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting TGF-beta and the extracellular matrix in Marfan's syndrome.

Developmental cell - 1 Jul 2008

Kalluri Raghu, Han Yuchi

Abstract excerpt

Marfan's syndrome is a genetic disorder affecting connective tissues, and it can lead to death due to aortic defects if left untreated. beta-blocker therapy has been used to slow the progression of this disease. Brooke et al. (2008) now report that combining angiotensin II receptor blockade by losartan with beta-blocker treatment is an effective treatment combination therapy for this disorder.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin II Type 1 Receptor Blockers
Share to Extracellular Matrix
Share to Fibrillins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Losartan

Share to Marfan Syndrome

Share to Microfilament Proteins

Share to Radiography

Share to Transforming Growth Factor beta

Source

Identifiers

PMID: 18606132
DOI: 10.1016/j.devcel.2008.06.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting TGF-beta and the extracellular matrix in Marfan's syndrome.PMID 18606132Read ↗

Therapeutic management of patients with Marfan syndrome: focus on cardiovascular involvement.Semantic proximity Read ↗

Pathophysiology and Management of Cardiovascular Manifestations in Marfan and Loeys–Dietz SyndromesSemantic proximity Read ↗

Marfan syndrome: from gene to therapy.Semantic proximity Read ↗

Connective tissue disorders and cardiovascular complications: the indomitable role of transforming growth factor-beta signaling.Semantic proximity Read ↗

Recent advances in understanding Marfan syndrome: Should we now treat surgical patients with losartan?Semantic proximity Read ↗

Development of novel therapies for Marfan syndrome using a human iPSC-disease modelSemantic proximity Read ↗

Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.Semantic proximity Read ↗

TGF-β–dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndromeSemantic proximity Read ↗

Development of a zebrafish model of Loeys-Dietz syndrome through tgfbr2b knockdown.Semantic proximity Read ↗

Determination of the molecular basis of Marfan syndrome: a growth industrySemantic proximity Read ↗

Recent developments in the diagnosis of Marfan syndrome and related disorders.Semantic proximity Read ↗

[Novel pharmacological strategies for aortic dilation in Marfan syndrome: from mouse models to human patients].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.